LATEST FROM IPOX^®

News

News and updates from IPOX^®, including media mentions, interviews, research and press releases.

Media mentions · Reuters

Reuters: IPOX^® Associate Lukas Muehlbauer Comments on Kailera Therapeutics' Nasdaq Debut

IPOX^® Research Associate Lukas Muehlbauer was featured in a recent Reuters article discussing Kailera Therapeutics' $625 million IPO. As shares surged 62.5%, the debut signals a potential biotech IPO market turnaround. Muehlbauer highlighted the strong demand for GLP-1 companies, stating, "Obesity remains one of the few areas in biotech with clear investor appetite." He noted near-term trading relies heavily on broader obesity-drug space fundamentals.

April 17, 2026Lukas Muehlbauer

Media mentions · Reuters

Reuters: IPOX^® VP Kat Liu Comments on Madison Air's Strong NYSE Debut

Reuters highlighted Madison Air Solutions' highly successful NYSE debut, where shares surged to secure a massive 15.65 billion dollar valuation. Raising 2.23 billion dollars, the HVAC firm achieved the largest industrials listing since 1999, driven by robust demand for AI data center cooling infrastructure. IPOX^® Vice President Kat Liu provided expert commentary on the blockbuster offering, noting that its heavy oversubscription and premium pricing signal a definitive return of investor appetite for proven cash generating businesses despite an uneven market.

April 17, 2026Kat Liu

Media mentions · Nikkei

Nikkei: IPOX^® Founder Josef Schuster Comments on Resilient IPO Market for Defense Tech

The number of defense-tech unicorns in North America has risen to 24, four times the 2020 level. Heightened geopolitical risks, including military clashes involving the U.S., Israel, and Iran, are driving investment into defense companies. As unicorns continue to emerge, the initial public offering market is also becoming more active. IPOX^® CEO Josef Schuster said, "Because it is less directly affected by stock market volatility, the IPO market in the defense sector is quite robust."

April 15, 2026Josef Schuster

Media mentions · Reuters

Reuters: IPOX^® Associate Muehlbauer Comments on U.S. IPO Resilience

A slew of companies across sectors, from biotech to real estate investment trust, launched IPO roadshows on Monday, as issuers prepare to go ahead with their listing plans amid the Middle East conflict. The IPO market struggled for momentum in February and March as episodes of market volatility sidelined issuers. But "2026 is still on track to be the best year for IPOs since the post-pandemic drought, and it may even get there without the mega listings," said Lukas Muehlbauer.

April 13, 2026

Media mentions · Reuters

Reuters: IPOX^® Associate Muehlbauer Highlights Sector Momentum in HawkEye 360’s IPO Filing

IPOX^® Associate Muehlbauer highlighted the growing momentum in the space technology sector following HawkEye 360’s U.S. IPO filing. He noted that while the anticipated SpaceX listing acts as a massive thematic catalyst, it could simultaneously divert investor focus from smaller issuers. Muehlbauer observed that HawkEye is strategically entering the public market during a favorable issuance window to manage debt from its recent acquisition of Innovative Signal Analysis, leveraging its 74% revenue jump and transition to profitability to attract disciplined investors.

April 10, 2026

Media mentions · Reuters

Reuters: IPOX^® Associate Lukas Muehlbauer Comments on AEVEX's IPO and the Defense 'Supercycle'

IPOX^® Associate Muehlbauer was featured in a recent Reuters article discussing the drone manufacturer AEVEX’s upcoming $2.35 billion IPO. Providing expert analysis on the growing investor appetite for defense technologies, he highlighted how rising global military spending has created a new defense 'supercycle.' He noted that conflicts in Ukraine and the Middle East underscore the critical role of modern unmanned systems, driving thematic investor interest in the rapidly expanding global drone sector.

April 9, 2026Lukas Muehlbauer

Media mentions · Bloomberg

Bloomberg: IPOX^® Associate Lukas Muehlbauer on European IPO Lock-Up Expirations

IPOX^® Associate Muehlbauer was featured in a Bloomberg article discussing the challenges facing European IPOs as lock-up periods expire. With many 2025 listings trading significantly below their offer prices, Muehlbauer noted that while selling at a discount can "lock in a disappointing valuation," strategic follow-on sales may ultimately benefit companies by improving liquidity and reducing market overhang. His analysis highlights the complex balancing act for investors navigating a thawing European equity market and shifting valuation benchmarks.

April 8, 2026Lukas Muehlbauer

Media mentions · Reuters

Reuters: IPOX^® CEO Josef Schuster Cautions on Pricing Realities Ahead of SpaceX's Mega IPO

A recent Reuters article explores how SpaceX’s anticipated $75 billion IPO could overshadow other listings and absorb a massive share of investor capital, potentially delaying a broader U.S. IPO market revival until 2027. IPOX^® CEO Josef Schuster provided expert commentary on the current listings environment, cautioning that even high-profile debuts cannot escape current market realities. He emphasized that the U.S. remains a buyer’s market, requiring even strong candidates in hot sectors to demonstrate pricing flexibility to achieve IPO success.

April 7, 2026Josef Schuster

Media mentions · Reuters

Reuters: IPOX^® CEO Josef Schuster Comments on National Healthcare Properties' IPO Filing and Market Trends

National Healthcare Properties has filed for a U.S. IPO, becoming the latest real estate investment trust (REIT) to enter the public markets this year. Amid market volatility and caution regarding AI-driven disruptions, defensive sectors like REITs are gaining traction. IPOX^® CEO Josef Schuster notes that the IPO window remains wide open for U.S. firms insulated from economic shifts and tech valuation resets. He highlights healthcare REITs as a bright spot offering attractive dividend yields, uncorrelated stability, and strong recent performance.

April 6, 2026Josef Schuster

News

Stay ahead of the next listing.